Best Second-Line Treatments for Metastatic Colorectal Cancer
Author Information
Author(s): Sun Chengyu, Fan Enguo, Huang Luqiao, Zhang Zhengguo
Primary Institution: The Affiliated Xuzhou Clinical College of Xuzhou Medical University, Xuzhou Central Hospital, Xuzhou, Jiangsu, China
Hypothesis
What is the optimal second-line systemic treatment for metastatic colorectal cancer (mCRC)?
Conclusion
FOLFOX + Bevacizumab is likely the best second-line treatment for most patients with mCRC, while FOLFIRI + Bevacizumab + Panitumumab is recommended for those with RAS mutations.
Supporting Evidence
- FOLFOX + Bevacizumab + Erlotinib showed significant superiority in overall survival.
- Irinotecan + CMAB009 had advantages in improving progression-free survival.
- FOLFIRI + Trebananib had a significant advantage in improving overall response rate.
- Subgroup analyses indicated different optimal treatments for RAS-mutant and RAS-wild-type populations.
Takeaway
Doctors found that a combination of certain medicines works best for people with advanced colon cancer who need a second round of treatment.
Methodology
The study analyzed 47 randomized controlled trials using Bayesian network meta-analysis to compare second-line treatments for mCRC.
Potential Biases
Some studies included were open-label, which may introduce bias.
Limitations
The study did not include patients with MSI or BRAF mutations, which limits the generalizability of the findings.
Participant Demographics
The included studies involved 16,925 patients, mostly men, with a median age between 55 and 70 years.
Statistical Information
P-Value
0.31
Confidence Interval
95% CI: 0.13–0.75
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website